Skip to main content
Caplight Logo









Shanghai Unicar-Therapy Bio-medicine Technology

Shanghai Unicar-Therapy Bio-medicine Technology

Private
ShanghaiHealthcare & Life Scienceshttp://www.unicar-therapy.com/

Last Round

Series C

Aug 26, 2022

Total Funding Raised

$8.2M

Company Overview

Shanghai Unicar-Therapy Bio-medicine Technology is a biotechnology company that develops cellular immunotherapy drugs and CAR-T therapies for oncology treatment.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

CAR-T cell therapyimmunotherapycancer immunotherapycell therapyoncologybiotechdrug discoverybiopharmaceuticalsolid tumor therapyhematological malignanciesgene regulationantibody discoveryclinical trialsprecision medicinenext-gen CAR-T

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Shanghai Unicar-Therapy Bio-medicine Technology Comparables

Compare Shanghai Unicar-Therapy Bio-medicine Technology with similar companies based on industry and business-model similarity.

Shanghai Unicar-Therapy Bio-medicine Technology comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Juventas Cell Therapy Ltd.
88%
Shanghai YaKe Biotechnology Co., Ltd.
88%
Chongqing Precision Biotech Co., Ltd.
88%

Shanghai Unicar-Therapy Bio-medicine Technology Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series CAug 26, 2022
Series BMar 30, 2021
Series AJun 1, 2019
AngelMar 1, 2016

Shanghai Unicar-Therapy Bio-medicine Technology Investors

Notable investors and investment history

Shanghai Unicar-Therapy Bio-medicine Technology investors
InvestorRounds
Alwin CapitalSeries A
Junci InvestmentSeries C
Apricot CapitalAngel

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 26, 2022

    Raised $4M with Junci Investment participating

  • Jun 1, 2019

    Raised Series A with Alwin Capital and Hainan Haiyao Co Ltd.

Shanghai Unicar-Therapy Bio-medicine Technology Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Shanghai Unicar-Therapy Bio-medicine Technology Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Shanghai Unicar-Therapy Bio-medicine Technology's valuation, stock price, and market status.

Firmographic Details

HeadquartersShanghai
Employee Range12
Year Founded2015
Last FundingAug 26, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?